Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA4 | P22748 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575379 | 0.95 | PTGDR2 (0.44) | PPARGPPARAPTGDR2CETPALDH1A1 | |
| SCHEMBL4575057 | 0.89 | PPARG (0.44) | PPARGPPARACETPPPARDTRPM8 | |
| SCHEMBL14277961 | 0.88 | PPARD (0.49) | PPARGPPARAPPARD | |
| SCHEMBL4575151 | 0.86 | ALDH1A1 (0.44) | PPARGPPARAALDH1A1PPARDGAA | |
| SCHEMBL4575418 | 0.85 | PPARG (0.46) | PPARGPPARACETPPPARD | |
| SCHEMBL4575605 | 0.83 | PPARA (0.48) | PPARGPPARAALDH1A1PPARDTRPM8 | |
| SCHEMBL4574670 | 0.82 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4575888 | 0.82 | PPARG (0.45) | PPARGPPARACETPPPARD | |
| SCHEMBL4575127 | 0.81 | CETP (0.40) | CETPALDH1A1TRPM8 | |
| SCHEMBL4574721 | 0.80 | PPARA (0.39) | PPARGPPARAALDH1A1PPARDTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1090972-B1 | Solvent-free two-component curable adhesive composition | MITSUI TAKEDA CHEMICALS INC (JP) | 2005-05-04 | — | — | EP | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| US-6538095-B2 | For laminating metal foil with a plastic film, prevention of leakage | MITSUI TAKADA CHEMICALS INC. (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020143133-A1 | Solvent-free two-component curable adhesive composition | IMAI AKIHIRO (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1090972-A2 | Solvent-free two-component curable adhesive composition | Takeda Chemical Industries, Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | CA12 4716/4885CA1 4355/4885CA2 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.